Novo Nordisk reports encouraging Phase 3 results for yet another diabetes treatment. Liraglutide is a human analogue of a naturally occurring hormone. Novo is developing it for the treatment of type 2 diabetes and hopes to submit it for regulatory approval in mid-2008. (Editorial note: I really respect Novo’s business model re: diabetes. Focus, focus, focus!)

EyeonFDA blog reports that the FDA drug approval rate ain’t what it used to be. I think we all knew that, but the article has a link with numbers, if you’re into that.

Eye-opening letter from Jim Cornelius, CEO of BMS, to employees, addressing an upcoming need to reorganize (read: downsize). It’s an interesting one, actually. There is a bit of corporate-speak, as in these phrases: “…as part of resetting our cost base, there would need to be headcount reductions in some parts of the company…The changes we are considering center around the transformation of our model to execute our strategy…Your compliance and integrity will be vital as, moving forward with our productivity transformation, we will empower decision-making at the appropriate levels throughout the company.” But, to be fair, other parts of the letter are pretty plain and straightforward…for a CEO.